Neovacs Balance Sheet Health
Financial Health criteria checks 6/6
Neovacs has a total shareholder equity of €49.3M and total debt of €1.5M, which brings its debt-to-equity ratio to 3%. Its total assets and total liabilities are €57.0M and €7.7M respectively.
Key information
3.0%
Debt to equity ratio
€1.50m
Debt
Interest coverage ratio | n/a |
Cash | €6.19m |
Equity | €49.27m |
Total liabilities | €7.72m |
Total assets | €56.99m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0LW's short term assets (€8.5M) exceed its short term liabilities (€3.9M).
Long Term Liabilities: 0LW's short term assets (€8.5M) exceed its long term liabilities (€3.8M).
Debt to Equity History and Analysis
Debt Level: 0LW has more cash than its total debt.
Reducing Debt: 0LW's debt to equity ratio has reduced from 17.9% to 3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0LW has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0LW has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 15.4% each year.